Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial-Reference-Cited by-同舟云学术

Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial

Published:2023-02 Issue:2 Volume:115 Page:305-316
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Tree Alison C.,Satchwell Laura,Alexander Emma,Blasiak-Wal Irena,deSouza Nandita M,Gao Annie,Greenlay Emily,McNair Helen,Parker Chris,Talbot James,Dearnaley David,Murray Julia

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference44 articles.

1. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial;Dearnaley;Lancet Oncol,2007

2. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial;Dearnaley;Lancet Oncol,2016

3. Cancer Research UK. Cancer statistics UK 2018. Available at: https://crukcancerintelligence.shinyapps.io/EarlyDiagnosis/. Accessed June 1, 2022.

4. Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models?;Tree;Clin Oncol,2014

5. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial;Pollack;Int J Radiat Oncol Biol Phys,2002

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial;International Journal of Radiation Oncology*Biology*Physics;2024-09

2. Long-term Results of Hypofractionated Radiotherapy With Intra-prostatic Boosts in Men With Intermediate- and High-risk Prostate Cancer: A Phase II Trial;Clinical Oncology;2024-08

3. The expanding role of radiation oncology across the prostate cancer continuum;Abdominal Radiology;2024-06-20

4. Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicity;Clinical and Translational Radiation Oncology;2024-05

5. Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial;Radiotherapy and Oncology;2024-04